HK1040246B - 1-(4-羥苯基)-2-(4-羥基-4-苯基哌啶-1-基)-1-丙醇的甲磺酸鹽三水合物的製備方法 - Google Patents
1-(4-羥苯基)-2-(4-羥基-4-苯基哌啶-1-基)-1-丙醇的甲磺酸鹽三水合物的製備方法Info
- Publication number
- HK1040246B HK1040246B HK02101962.0A HK02101962A HK1040246B HK 1040246 B HK1040246 B HK 1040246B HK 02101962 A HK02101962 A HK 02101962A HK 1040246 B HK1040246 B HK 1040246B
- Authority
- HK
- Hong Kong
- Prior art keywords
- phenylpiperidin
- hydroxyphenyl
- propanol
- hydroxy
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20067300P | 2000-04-28 | 2000-04-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
HK1040246A1 HK1040246A1 (en) | 2002-05-31 |
HK1040246B true HK1040246B (zh) | 2005-10-28 |
Family
ID=22742684
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK02101962.0A HK1040246B (zh) | 2000-04-28 | 2002-03-14 | 1-(4-羥苯基)-2-(4-羥基-4-苯基哌啶-1-基)-1-丙醇的甲磺酸鹽三水合物的製備方法 |
Country Status (27)
Country | Link |
---|---|
US (1) | US6645986B2 (zh) |
EP (2) | EP1151995B1 (zh) |
JP (2) | JP3615496B2 (zh) |
KR (1) | KR100442718B1 (zh) |
CN (2) | CN1590373A (zh) |
AR (1) | AR028376A1 (zh) |
AT (1) | ATE277014T1 (zh) |
AU (1) | AU781436B2 (zh) |
BR (1) | BR0101630A (zh) |
CA (1) | CA2345582C (zh) |
CZ (1) | CZ20011471A3 (zh) |
DE (1) | DE60105689T2 (zh) |
DK (1) | DK1151995T3 (zh) |
ES (1) | ES2227071T3 (zh) |
HK (1) | HK1040246B (zh) |
HU (1) | HUP0101723A3 (zh) |
ID (1) | ID30006A (zh) |
IL (1) | IL142705A0 (zh) |
IN (1) | IN191027B (zh) |
PL (1) | PL347298A1 (zh) |
PT (1) | PT1151995E (zh) |
RU (1) | RU2203888C2 (zh) |
SI (1) | SI1151995T1 (zh) |
TR (1) | TR200402696T4 (zh) |
TW (1) | TW200505858A (zh) |
YU (1) | YU27701A (zh) |
ZA (1) | ZA200103320B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2635452A1 (en) * | 2000-06-21 | 2001-12-27 | Bioarray Solutions, Ltd. | Looped probe design to control hybridization stringency |
US6743921B2 (en) | 2002-01-24 | 2004-06-01 | Dsm Catalytica Pharmaceuticals, Inc. | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds |
CN1930304B (zh) | 2003-11-21 | 2016-01-06 | Anp技术公司 | 不对称支化的聚合物缀合物和微阵列检测 |
ATE496297T1 (de) | 2005-05-02 | 2011-02-15 | Anp Technologies Inc | Polymerkonjugat-verbesserte bioassays |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100291882B1 (ko) * | 1995-08-11 | 2001-10-26 | 디. 제이. 우드, 스피겔 알렌 제이 | (1에스,2에스)-1-(4-하이드록시페닐)-2-(4-하이드록시-4-페닐피페리딘-1-일)-1-프로판올메탄설포네이트트리하이드레이트 |
-
2001
- 2001-04-18 YU YU27701A patent/YU27701A/sh unknown
- 2001-04-19 IL IL14270501A patent/IL142705A0/xx not_active IP Right Cessation
- 2001-04-20 IN IN358MU2001 patent/IN191027B/en unknown
- 2001-04-23 TW TW093121004A patent/TW200505858A/zh unknown
- 2001-04-23 JP JP2001124290A patent/JP3615496B2/ja not_active Expired - Fee Related
- 2001-04-23 US US09/840,580 patent/US6645986B2/en not_active Expired - Fee Related
- 2001-04-24 SI SI200130191T patent/SI1151995T1/xx unknown
- 2001-04-24 ES ES01303705T patent/ES2227071T3/es not_active Expired - Lifetime
- 2001-04-24 DK DK01303705T patent/DK1151995T3/da active
- 2001-04-24 ZA ZA200103320A patent/ZA200103320B/xx unknown
- 2001-04-24 EP EP01303705A patent/EP1151995B1/en not_active Expired - Lifetime
- 2001-04-24 AT AT01303705T patent/ATE277014T1/de not_active IP Right Cessation
- 2001-04-24 DE DE60105689T patent/DE60105689T2/de not_active Expired - Fee Related
- 2001-04-24 PT PT01303705T patent/PT1151995E/pt unknown
- 2001-04-24 TR TR2004/02696T patent/TR200402696T4/xx unknown
- 2001-04-24 EP EP04013748A patent/EP1477479A1/en not_active Withdrawn
- 2001-04-25 CZ CZ20011471A patent/CZ20011471A3/cs unknown
- 2001-04-26 AU AU38896/01A patent/AU781436B2/en not_active Ceased
- 2001-04-26 AR ARP010101971A patent/AR028376A1/es unknown
- 2001-04-26 ID IDP20010342A patent/ID30006A/id unknown
- 2001-04-26 CA CA002345582A patent/CA2345582C/en not_active Expired - Fee Related
- 2001-04-27 RU RU2001111947/04A patent/RU2203888C2/ru not_active IP Right Cessation
- 2001-04-27 CN CNA2004100586743A patent/CN1590373A/zh active Pending
- 2001-04-27 BR BR0101630-0A patent/BR0101630A/pt not_active IP Right Cessation
- 2001-04-27 CN CNB011171715A patent/CN1210262C/zh not_active Expired - Fee Related
- 2001-04-27 PL PL01347298A patent/PL347298A1/xx not_active Application Discontinuation
- 2001-04-27 HU HU0101723A patent/HUP0101723A3/hu unknown
- 2001-04-28 KR KR10-2001-0023208A patent/KR100442718B1/ko not_active IP Right Cessation
-
2002
- 2002-03-14 HK HK02101962.0A patent/HK1040246B/zh not_active IP Right Cessation
-
2004
- 2004-03-12 JP JP2004071015A patent/JP2004196823A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1051681A1 (en) | New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole. | |
EG23951A (en) | Cilostazol preparation | |
IL146162A0 (en) | Macrolide compounds for the treatment of dry eye | |
IL153505A0 (en) | Dds compound and process for the preparation thereof | |
IL154458A0 (en) | Processes for preparing cilostazol | |
HK1040246B (zh) | 1-(4-羥苯基)-2-(4-羥基-4-苯基哌啶-1-基)-1-丙醇的甲磺酸鹽三水合物的製備方法 | |
IL133760A0 (en) | Composition for the treatment of dandruff | |
HK1040514B (zh) | 1-(4-羥基苯基)-2-(4-羥基-4-苯基哌啶-1-基)-1-丙醇的甲基磺酸鹽三水合物和對其有用的中間體的製備方法 | |
HUP0200842A3 (en) | Combination preparation for treating malaria | |
HUP0001558A3 (en) | Process for the preparation of pirlindole hydrochloride | |
HU0600400D0 (en) | A new process for preparing magnesium salt of the s-omeprazole trihydrate | |
EP1398054A4 (en) | METHOD OF ACCELERATING THE IMPROVEMENT OF THE SKIN BARRIER FUNCTION | |
HRP20020098A2 (en) | Process for the preparation of isotretinoin | |
IL147298A0 (en) | Process for the preparation of substituted benzisothiazole compounds | |
AU2003207409A1 (en) | Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds | |
TW376840U (en) | Improvement of the cutter seat for the angle chamferring machine for marbles | |
TW448811U (en) | Surface treatment machine for aluminum frame | |
TW485843U (en) | Improved structure for crumbling machine | |
TW502660U (en) | Improved structure for crumbling machine | |
GB9929918D0 (en) | Adjustable tattoo machine | |
TW418672U (en) | Minutely-adjustable bi-polarizating skin microscopic photographing machine | |
GB9914848D0 (en) | Shape conforming surface | |
GB0020105D0 (en) | Surface treatment tool |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20090427 |